Feedback / Questions
laruparetigene zovaparvovec (AGTC-501) - AGTC
https://www.prnewswire.com/news-releases/beacon-therapeutics-announces-arvo-2025-presentation-on-preliminary-6-month-data-from-its-phase-2-dawn-trial-of-laru-zova-in-patients-with-x-linked-retinitis-pigmentosa-xlrp-302437302.html
Apr 24, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next